Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter

BACKGROUND: Nearly all patients with newly diagnosed glioblastoma experience recurrence following standard-of-care radiotherapy (RT) + temozolomide (TMZ). The purpose of the phase III randomized CheckMate 548 study was to evaluate RT + TMZ combined with the immune checkpoint inhibitor nivolumab (NIV...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Michael, Weller, Michael, Idbaih, Ahmed, Steinbach, Joachim, Finocchiaro, Gaetano, Raval, Raju R, Ansstas, George, Baehring, Joachim, Taylor, Jennie W, Honnorat, Jerome, Petrecca, Kevin, De Vos, Filip, Wick, Antje, Sumrall, Ashley, Sahebjam, Solmaz, Mellinghoff, Ingo K, Kinoshita, Masashi, Roberts, Mustimbo, Slepetis, Ruta, Warad, Deepti, Leung, David, Lee, Michelle, Reardon, David A, Omuro, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629431/
https://www.ncbi.nlm.nih.gov/pubmed/35511454
http://dx.doi.org/10.1093/neuonc/noac116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629431/
https://www.ncbi.nlm.nih.gov/pubmed/35511454
http://dx.doi.org/10.1093/neuonc/noac116

Ejemplares similares